Skip to content
DataLookout
Menu

NCT07081555

A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

StatusRecruiting
PhasePhase 1
SponsorAffibody
Primary completion (estimated)

At risk: Primary completion moved 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 10 words Show 4 more changesShow less
    • Primary completion pushed from Jan 1, 2027 to Jun 1, 2027
    • Study sites: 3 to 4
    • Secondary endpoints: details revised at 2 of 3 entries
    • Study description revised
  2. Notable Start date: Aug 1, 2025 to Oct 6, 2025v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Treatment emergent adverse events
Timeframe: From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43
Dose Limiting Toxicities
Timeframe: From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43

Secondary (3)

Absorbed dose in gray (Gy) per organ and selected tumors
Absorbed dose coefficient (Gy/GBq) per organ and selected tumors
Normalized whole-body effective dose (millisieverts [mSv]/MBq)

Arms and interventions

Part AExperimental

\[177Lu\]Lu-ABY-271

Part B - Cohort 1Experimental

\[177Lu\]Lu-ABY-271 with protein mass dose A

Part B - Cohort 2Experimental

\[177Lu\]Lu-ABY-271 with protein mass dose B

Part B - Cohort 3Experimental

\[177Lu\]Lu-ABY-271 with Protein mass dose C

Drugs: [177Lu]Lu-ABY-271

Sites

4 sites in 2 countries

Sweden 3, Norway 1